What if Alzheimer’s isn’t a single disease – but a combination of hidden root causes?
In this episode of The Evolution of Medicine, James Maskell and Dr. Kristine Burke explore how cognitive decline can be reversed by addressing underlying drivers like toxins, inflammation, and metabolic dysfunction.
You’ll learn how a functional medicine approach – focused on personalized care and early intervention – is already helping patients regain cognitive function.
This is a conversation about hope, prevention, and a new future for brain health.
About the Guest:
Dr. Kristine Burke is a physician specializing in functional medicine with a focus on reversing chronic diseases, including Alzheimer’s and cognitive decline. After years in conventional family medicine, she shifted her approach to address root causes – helping patients achieve meaningful recovery through personalized, systems-based care.
– – – – –
About the Host:
James Maskell is a healthcare entrepreneur and founder of The Evolution of Medicine. For over 20 years, he has worked to scale functional medicine through community-driven models, group visits, and practitioner infrastructure. His work focuses on moving medicine upstream – toward prevention, lifestyle intervention, and systems-based care.
Website: https://www.jamesmaskell.com/
Instagram: https://www.instagram.com/mrjamesmaskell
Facebook: https://www.facebook.com/jamesedwardmaskell/
LinkedIn: https://www.linkedin.com/in/jamesmaskell
Thank you for listening.
Please subscribe and share.
This podcast is produced by DrTalks.com
https://drtalks.com/podcast-service/
Listen wherever you listen to your podcast or watch the full episode on our YouTube channel.
Transcript:
In the Precision medicine group, we saw substantial improvements in memory, in cognitive performance, in, uh, cognitive symptom burden improved. And overall, we had a 92% reported improvement rate. And in the standard treatment group, the randomized controlled trial where we compare the intervention to the control group, and in the control group, we saw minimal.
Symptom improvement. We actually saw declines in memory performance as opposed to the stark, uh, improvement that we saw in the intervention group and declines in memory and cognitive performance. Hello and welcome back to the Reversing Alzheimer’s 2.0 Summit, and I’m here today with my co-host, Dr.
Christine Burke, and we are gonna be giving you an update as to what you can expect in this year’s summit, how it builds upon what we did last year, and all the things you can learn are when you join us. This April for the summit. So Dr. Bur, welcome. Hi. Nice to be here. I’m so excited about the summit that we’ve pulled together this year.
What a time for talking about reversal Alzheimer’s. Ultimately those of us, and, and I would say those of you, because this is your work, have, have been sort of implementing these ideas in clinical practice now for a number of years, have seen firsthand what’s possible when you use a different way of treating the brain that is the standard of care.
But I would say if there’s one thing that happened in the last year that’s probably the most exciting, it’s sort of, um, a continued accelerated progress towards proving that this is a, this. Of the, the results that are possible in your practice that these are possible generally. Yeah, I agree. Completing the study and the dementia reversal clinical trial study and analyzing those results, getting it into pre-print and now in submission for, uh, the Journal of Alzheimer’s Disease is really a monumental milestone for this work moving forward.
So great. So I know that you have done an interview with Dr. Dale Bredeson and Dr. Kat tubes all about the study. If people wanna know more about it, what will they learn if they come onto that interview? Yeah. Well, this study was a randomized controlled trial over three years, across six different sites in the country, and we were looking at a precision medicine approach to reverse cognitive decline in.
And early Alzheimer’s disease. So the key results were that precision medicine group was compared to a control group. And in the Precision medicine group, we saw substantial improvements in memory, in cognitive performance, in, uh, cognitive symptom burden improved. And overall, we had a 92% reported improvement rate, which was really cool.
And in the standard treatment group, ’cause this is the gold standard, right? The randomized controlled trial where we compare the intervention to the control group. And in the control group we saw minimal symptom improvement. We actually saw declines in memory performance as opposed to the stark uh, improvement that we saw in the intervention group and declines in memory and cognitive performance.
So really, really strong, statistically significant. If you’re into statistics, the P values are less than 0.001, so that means. Less than one in a thousand chance that these results occurred by chance as opposed to as a result of the intervention. So really amazing outcomes. I know that, you know, for the last decade, Dr.
Bressen has been, you know, working to essentially prove that this methodology or his methodology, you know, can be effective. What does it mean for the industry to have a randomized control trial compared to some of the other data points that have have come together over the last decade? Yeah, well, in a randomized controlled trial as opposed to what’s been, uh, shown before with the pilot study, you’re comparing to that control group.
So when you compare to the standard of care, then you really have the opportunity to say, this intervention has a different result, a different outcome than what that does. And that’s what makes this really, uh, really groundbreaking. Wonderful. Well, I would encourage everyone who is listening to this to make sure to check out that interview because you have.
Three of the leaders of this movement, you know, really bringing to light what they learned from it and, uh, and to see what the implications are for both caregiving, for patients, for clinical practice, and for, for the standard of care. I’d love to just say, you know, obviously over the last year we’ve, um, we’ve taken a lot of ground in trying to think about, okay, well how could this become the standard of care?
And I guess start by. Just asking, you know that the doctors that were chosen for that study, you know, they have a lot of things in common, but one of them is that these are people with deep expertise, experience, people who have been doing this medicine for a long time to get those kind of outcomes. What out of that?
Gives you hope for a new standard of care, and one out of that gives you some like trepidation. Well, I think one of the interesting things is that almost all of us are family physicians, and so that’s really a big paradigm shift in terms of how we think about the treatment of this disease being kind of an end stage diagnosis.
Then a referral to neurology for management. Really management of the decline that’s typical of that disease. And now what we have is this opportunity for primary care to become the place where we identify the earliest changes in cognition, the earliest changes in memory, the earliest changes really in how proficiently a brain is working, and we can implement these interventions then.
To hopefully prevent the progression to what we’ve now shown we can, we can reverse on the other side. So that’s a very exciting change. I think, you know, one of the things that makes this work challenging is that it’s an enormous amount of data to. To integrate, to synthesize, and to develop a treatment plan based on the functional, integrative precision medicine paradigms of systems biology and the system interconnectedness.
And so that’s definitely one of the challenges, and I think that’s one that you and I have been working really hard to solve with True Neuro, creating a system of organization for clinicians to be able to do this work well. Absolutely. And yeah, just to flesh that out for people who, you know, are listening to this for the first time, Dr.
Burke and I, um, are in, uh, are in the process of looking to solve this problem. And, you know, one of the things that we would love to see and that the vision for the company is that this could become the standard of care. And that ultimately that, uh, that cognitive decline would be something that. You know, it, it may still happen, but it would be unlikely, or it would be that there would be a standard of care available to everyone where, where cognitive decline would not be the standard outcome.
And ultimately, you know, one of the things that has to happen for that to happen is we have to really, uh, the work that has been done to the next level, specifically as making it easier for practitioners to do this work because I have so much reverence for all the people that have come before us and have proven some, some of these outcomes.
But ultimately, you know, that level of commitment to decades of training outside of the standard of care is not something that I think we can expect of every doctor. Therefore we have to really start to think about how to, to make that easier. And I would say over the last year, one of the big things is establishing the technology, getting it out, getting clinics using it, and then being in a process to mentor other clinicians.
What’s it been like to sort of put on a mentor hat every week and support clinicians who were just finding their way? Into either finding their way or looking to accelerate their ability to deliver this to their community. Yeah, well, I mean, you know me very well and so, you know, I love teaching and you know, I’ve been teaching for various organizations and in, you know, various.
With Loma Linda University and other, other organizations. And so I’ve used all of those skills in my own center as I’ve trained clinicians that have joined our team that’s now, you know, grown to five, five practitioners. But it’s been fun to bring that into a new group where it isn’t necessarily people who are coming in and working with me.
It’s people in all of their different practices and their different ecosystems, and even different specialties. And so bringing that group together. And having the opportunity to teach about the work that I do, that we do at our center, that we’ve done what we’ve accomplished in the study, and then get feedback from people and hear different ways that they’ve been able to either incorporate things or tips or tricks that they’ve uncovered in their practice.
And then having that group of people together really elevating each other has been a, a piece of that that I didn’t really anticipate. Wonderful. Well, the good news is that if you’re listening to this, that the, you know, the network is being built to be able to be supportive of, of everyone, to have this sort of standard of care, and it’ll certainly take some time, but we are both deeply committed to that process as is, you know, everyone who’s involved in it.
I just wanted to share from my perspective, one of the, the great things that I’ve learned this year, a sort of a unifying moment for me was coming to a conference and hearing Dr. Bressen speak and him talking about. The strategy that you are working on. The idea that Alzheimer’s is a function of what he called network insufficiency.
So biological networks in the body, breaking down, becoming insufficient, and that leading to what we see as Alzheimer’s. And that’s in pretty direct contrast to if you look at, say something like the Alzheimer’s drug discovery pipeline. Where you are essentially looking for, you know, what is the mechanism of action that we’re gonna test, and then what molecule can solve for that mechanism of action.
And what, what struck me when I saw the diagram of that pipeline was that there were 14 different mechanisms of action that were being worked on. So either one of those will be right and the rest will be wrong, which. I think if that had happened, we would’ve already seen more progress than we have. But the fact that a networks insufficiency paradigm works on 92% of the people tells me that it, it, it sort of, um, it brings Dr.
Bredesen’s thesis that there’s a multifactorial illness. It seems like it couldn’t be more obvious, and I really appreciated the network insufficiency paradigm because. I wrote a book on, I would say, network insufficiency, which was really about what happens when loneliness, and what are the health effects of loneliness and what are the health effects of not having a community by which to implement the healthy behaviors that would allow your biological network to be sufficient.
And then even beyond that, the work that both of us are involved in now is to build network sufficiency of clinics that can deliver on this paradigm. And so. It’s been amazing to just spend time into that concept because I just see that actually if you, if you sort of take a step out. There’s one consistent theme that goes across all of these areas, and I think that part of my, what I see between maybe like now and and next year’s summit might be the popularization of the concept of network sufficiency as sort of a lightning rod to really understanding.
How do we work together to bring back human health? Just wanted to take a moment to thank our mission partners for helping bring this podcast to you. As you know, we are in the business of building a network of clinics that can reverse cognitive decline, and our partners in that are organizations. You can find out more if you go to goevomed.com and look.
At the Mission Partners, but first and foremost, Truneura. If you go to truneura.com, you can get a demo. Um, this is the underlying software that will connect this network of clinics. And we have an incredible mastermind session. A lot of cool stuff coming out of that company. Um, you can see here. Uh, Fullscript thanks to Fullscript with Fullscript where we’re gonna help you take advantage of the tools that they have, um, to compete with things like ChatGPT, and Function Health.
It’s gonna be awesome. Go to goevomed.com/fullscript. Uh, bigboost.marketing If you need patients for your clinic, uh, or if you have any marketing needs, goevomed.com/bigboost is, uh. Premier, uh, supporter in that world. And then please, uh, also check out Freedom Practice Coaching Built and scaled a very successful brain health practice and has been instrumental in helping practitioners with the nonclinical aspects of running a practice doing this.
These are our mission partners. These are people that I know well. These are people at the top of their sphere and really excited to bring you, uh, the rest of the podcast. Enjoy. I think it’s such an interesting concept, really. When you think about it, and it, and it does really contrast with how we have approached.
Chronic illness in particular, um, in medicine, and just the idea that, that we have this very complicated degenerative process in, in a number of different disease states and that we could have just one target that could turn that all around. The more we learn about this, the more ridiculous that that really seems.
But I think what we’re, those of us who are working on this particular part, the precision medicine approaches are hoping. Is that this combination of seeking out and correcting the root cause, contributors that are leading to, to degeneration, and specifically in this instance, neurodegeneration and ultimately Alzheimer’s disease, can potentially then in the future be combined with.
Maybe anti amyloid therapies after you fixed the fire, right after you fixed the underlying problem, then maybe there will be a place where these medications can be profoundly more effective than they are right now. And I think that’s what we’re, that’s what we’re kind of future casting or hoping that we’ll see.
Wonderful. Well, look, I’m, I’m very excited to be on this journey and, uh, you know, for anyone who’s here, who’s listening, if you’re a, a patient or a caregiver or someone who’s involved in that, you know, our hope is that we can really make it easy for you to find a practitioner that can deliver the standard of care.
Then if you’re a doctor, how can we make it easy for you to launch a program or a clinic? How can we make it easy for you to launch a program to deliver these, you know, these, uh, this kind of care, deliver episodes of care consistently, how to track the outcomes so that we can see across the network of clinic where the best outcomes are coming from, and we can continually learn from that process.
And then on the other side of it. On the third side is really starting to see, you know, what, what would it take to build capacity for the network? And that’s gonna be probably a life mission, but something that is well worth it when you see what’s possible on the other side. I wanted to just ask you, you know, if.
One of the things that has happened this year is you’ve been on national TV talking about a completely different topic, or is it completely different? Mm-hmm. The reversal of type two diabetes, you know, what is someone who is maybe one of the, the leading lights in the world in reversing cognitive decline with, with precision medicine?
What, what is the sim? What are the similarities and differences with reversing type two diabetes when you are on tv? Yeah, so the, the interesting part is that I actually found my way into cognitive decline work through two of the other chronic diseases that are highly prevalent in our society. DI Type two diabetes, what you just mentioned, and then also cardiovascular disease, the number one killer, and it was my work.
In both reversing type two diabetes, which is predominantly a lifestyle driven disease, your genetics may prime you to develop the problem, but it’s your choices and your exposures that cause the expression of that disease. And so we can unravel that and we can reverse that the majority of the time. So that’s very exciting.
Then my work in cardiovascular disease prevention because we, you know, we have tools now that are available to us, lab testing and imaging that can really help us understand the inflammatory risk in the vascular system that leads to the, the event like the heart attack or the stroke. So we can see these things coming long before we could before, and that gives us an opportunity to intervene and then both of those things.
Share common root causes, the metabolic dysfunction, the vascular wall injury, and leaky blood vessels that allow things to get into the brain. So all of those share common mechanisms with what drives Alzheimer’s disease or cognitive decline and, and neurodegeneration. It was really my previous work that set me up to understand the concepts that I needed to.
To grasp and to be able to apply and intervene on to reverse cognitive decline. It’s an interesting journey. Yeah. And, and ultimately cognitive decline is infinitely more complicated because there are all these other potential drivers. And I wanted to share, one of the best experiences I had in the last year was hearing your talk on mold illness because I think a lot of practitioners who were just coming into this space are surprise and patients too.
Mm-hmm. To understand that, you know, mold can be a driver of cognitive decline and is a driver frequently of cognitive decline. And when you were doing your presentation to the doctors in the mastermind, the practitioners, what I sort of took away from it was this was, you know, sort of 20 years of you going to conferences and learning and trying to package it in a way that, you know, this is all you need to know.
And obviously it’s a very complicated conversation because there’s diagnostic challenges, there’s patient implementation challenges, there’s all these different home challenges, but. Ultimately that, that’s the purpose of, of True Neuro is really to help practitioners identify what is driving the pathology.
And it was really amazing to just sort of feel that, uh, the synthesis happening in real time. Yeah, and I think you bring up a good point that there are two drivers that are frequently involved. Mold, obviously, as you just mentioned, is a very heavy one and it acts as a heavy. Anchor that holds down the progress or drags progress that’s been achieved back down once people have accomplished some improvement, if we don’t correct that.
And then the other area is chronic infections and like for example, I have a really interesting interview in the in the summit with Dr. Richard Horowitz, who has just had an article accepted into the Journal of Alzheimer’s Disease case reports. On using his DAP zone therapy for Lyme and TIC related illnesses to improve the cognitive outcomes for a patient, and actually to reverse elevated PTA two 17 levels, which is a marker that we’ll talk about both in the summit, and that is now becoming better known.
That tells us about the progress of the pathology of Alzheimer’s depe developing in someone’s brain. So all of these different pieces of the puzzle that are all. Specific areas that people have been focusing in actually all coalesce to impact the ultimate neurodegeneration and the development of cognitive decline.
Yeah, that’s such a great point. I’m really looking forward to watching that interview with Dr. Horowitz too. And I know, um, what a, what a, a key role that’s played in some of the cases in the mastermind. I’d love to you share, like, so one of the interviews I did with was with Dr. Christopher Shade and you know, one of the things that happened in between last year and this year was a dinner that we had in, in, uh, when you were both teaching at, uh, the Cognition 360 conference and the sort of mutual recognition of a, of a key concept that we talked about there, which is that time is brain.
And I think from your perspective, and you can share if I, if I’ve got this right, that one of the things, because when you’re working with a brain that’s in cognitive decline, you only have a limited window to intervene because the brain could be slipping away quickly. Time is brain. And the fact that you need to work out very rapidly what’s driving the cognition, cognitive decline, you don’t have time to wait.
And so you have to do all the testing. You have to get up to speed, so what’s going on? And then on Chris’s point of view, it was more like, okay, well. Once you have, once you know what’s going on, once you know what’s driving it, then the speed at which you could achieve outcomes is critical, and a lot of that is getting the nutrition.
Into the places where it needs to be in as a rapid way as possible. And so he brings the, the idea of, of using the, the delivery systems that, that he’s, he’s worked on. And, uh, we also shared a little bit about some of the, the, one of the tests that you used in the study, which was determining the source of the mercury and metals in the body.
And so it’s just, uh, it was interesting to see a unified concept coming from two different angles. That actually like, you know, the amount, you don’t have time to wait when it comes to this disease category. And uh, I’d love for you to just share your own, your own thoughts on that. Yeah, that was really, um, a watershed moment of understanding, I think for both of us, like you said.
’cause it’s like we’re working on the two, two sides of the same puzzle. You have to be able to identify what’s going on, but then you need to be able to get. Those toxins out of that person so that you can stop the chronic inflammation and the chronic oxidative stress and damage to the cells and the nucleus and the tissues, the organs that’s happening as a result of those.
And so it was, it was really interesting to see how we could bring those things together to try to accelerate outcomes. Beautiful. Mm-hmm. Well, another great interview that I did was with, uh, Robert Silverman, who I’ve known for a number of years since I, you know, punctual Forum started in New York 12 years ago.
And, you know, he talked about mitochondrial health and some of these other areas that really fit into the, the methodology. But one of the things that I heard him. Talking about that was interesting was zonulin, LPS and their effects on, on, uh, on Alzheimer’s. And I, I couldn’t help but think about some of the lectures and your sort of key thesis on barrier, uh, function.
And so maybe you could just share a little bit about that and then how you see that those two things, particularly zonulin and and LPS, fit into the overall picture of intervening through a network sufficiency model. Yeah, so I think it just. It brings us back to the concept that each of these different areas are connected in some way, and so, you know, increases in zonulin increase the, the gating in the gut to create leaky gut or open the channels in the gut.
And that can allow, you know, abnormal bacteria to get by larger proteins that can stimulate an immune response or, you know, low grade infections, various and toxins. And then we have that same process being stimulated by. LPS, which is endotoxin produced by certain types of gram-negative bacteria in the gut.
And that will then impact the blood-brain barrier. So it’s these two barrier systems that we have, the gut barrier and then the blood-brain barrier that are really both in. Ably linked in terms of protecting the brain. And so having so focusing on supporting both of those barrier systems is one of the main ways that we approach preventing cognitive decline.
And then repairing the damaged ones is a critical step in being able to reverse cognitive decline. This goes into your specialty of the vascular system. What are some of the strategies and tools that you like for repairing, uh, that dysfunction, and how do you identify that it’s happening? Yeah, so I mean, we know it’s happening because we see the degeneration happening.
It’s kind of like, how do you know you’ve had, you know, you have a leak, it’s because there’s a puddle. And so this is a bit like that, right? So we have the puddle that we’re seeing, the neurodegenerative mess that we’re dealing with. And so we know that these vascular disruptions have occurred. We know that these gut barrier disruptions have occurred, and so we have a whole toolkit that we use like in, in repairing the gut barrier integrity.
We have something called the our repair system that goes through a methodologic methodology of steps that help to repair. That barrier. And then for the blood brain barrier, we have to remove the toxins that are creating damage. We’ve gotta control the gut barrier so we don’t have LPS making its way up to the blood brain barrier.
And then we wanna be repairing that inner lining of the blood vessels, both the endothelium and then inside that the endothelial glycocalyx with things like ram and sulfate, a building block for that glycocalyx, that inner lining. So it is. There is, there is quite a bit of complexity to how we have to, how we have to go about doing it.
But just like anything else, once you learn the patterns and you learn the methodologies, then it becomes something that is readily reproducible. It’s interesting though, you know, because obviously it, it reinforces the need for this, this, uh, precision medicine approach because most people in that, if you’re listening to this and you’re a, you know, uh, someone who is either caring for someone or is, is experiencing it.
All you experience is the puddle. You know, you don’t really know where, where the leak is coming from. And ultimately, it’s interesting that you, you know that, that this is not something that can be necessarily fixed by a person. You need a care team. Look at your practice. You’ve got doctors and you’ve got PAs, and you’ve got nutritionists, and you’ve got health coaches.
At this moment in time, it seems to me that that is the only delivery system out in the world that can. That can consistently reverse this. You need that team approach. Absolutely. You need that team approach, and we replicated that team approach in the. Clinical trial so that we could get these types of results because you really do in the same, you have to have network sufficiency in your clinical team to be able to deliver all of the components of change that have to occur.
You have to have, the medical team has to have the right depth of testing tools. We can’t just be using the same blood tests that we used 40 years ago, have. A whole. We’ve got omics and bios and proteomics and organic acids. We have all of these new biochemical tools that tell us so much more about how the body is functioning rather than just whether it’s diseased or not, which is historically what we’ve typically used lab tests to help us identify.
So that’s a paradigm shift. Then we have to be able to retrain people in how they need to fuel their bodies so that they can heal and we need to help them to incorporate some of the lifestyle changes around getting enough exercise. Well, we gotta help them have enough energy to be able to exercise.
Before we can do that, we need to. Be removing the chemical toxin load from the home environment or from their work environment. So really at every level, there is a system that has to be addressed and each of those systems has to have complete sufficiency for the whole thing to work together. Wonderful.
Yeah, I love that use of it. It’s another, another good way of thinking about it in the, in the clinical team, um. Yeah. I guess the last thing I wanna just ask, so one of the great interviews that I did this year, which I was really excited to bring into this year’s summit was Dr. Garland Glenn, who very thoughtful, uh, functional neurologist, who’s been part of our mastermind at True Neuro for the last year and has added a lot of value.
And I think he’s really brought the sort of functional neurology concept to a group of clinicians, you know, really learning the network sufficiency model. And I just wanted to, you know, to, to give a shout out for his talk because. It seems like understanding the pathways and understanding the network is, is critical.
The state, the current state of the network. But one of the things I think he brings to it is the idea that, you know, that this is like a, a muscle that needs to be rebuilt in the patient and that ultimately some of it is doing the healthy things every day, but some of it is specifically brain training and different ways in which the eyes connect to the brain and all those different things that connect.
And I’d, I’d love to get your thoughts on, you know, just that, that. That addition to the methodology that you are familiar with and practicing? I absolutely love what Dr. Glenn brings to the Mastermind because it’s a perspective that people who’ve been trained as medical doctors have not seen. We have not been trained on that, and it really takes into account.
The power of neuroplasticity and then the specifics of training in certain ways. It’s kind of like, you know, it’s a little bit like the Olympics for the brain, right? Like you have to, you have to train in the way that you need the brain to function, and you have to be able to identify where the deficits are, where the weak points are, and build those up just like we would in physical therapy.
And so it’s really brought a perspective of. Of, um, capitalizing on that neuroplasticity, the ability of the brain to change and build new connections that allows it to do things that it’s lost. One of those things is retrieving memories, but one of those things may be retrieving words, or it might be remembering the process of how to do something or learning how to, you know, learning how to follow instructions again, because you can follow that sequence of events.
And we’ve typically approached it more from just kind of hoping or expecting those things to come back as people improve. And so it’s really exciting to see this whole field where we can apply specific assessments and then interventions and training protocols to help the brain improve faster.
Absolutely. I guess the, the last question I just wanna ask you is, it just feels like. There’s a lot of hope in this, in this field. You know, I think there’s a lot of noise Also online. There’s a lot of outrageous claims that are being made. It feels like there’s hope and that hope is grounded in real world outcomes that are done in a way that medicine respects the randomized control trial.
And maybe you could just speak to hope in context. I think, you know, whenever you accomplish something that. In a way no one else has done before. I mean, obviously Dr. Bredesen’s been working on this and Dr. Katu and, and Hathaway and Deborah Gordon and the pilot study and you know, Dr. Dean Ornish’s work.
So it’s not like there haven’t been people working on this, but really because this is the first RCT for this approach, we are the first to step out into the claim of being able to accomplish this. So I think that now that we’ve been able to really establish this in firmly in the literature that that hope is real.
It’s not a hope that maybe there will be something or maybe something will be discovered. It’s a hope grounded in factual accomplishment, and that completely changes the entire paradigm. It’s wonderful. Well, look, I, I think it’s really interesting how maybe this summit. It could be a marker of, of our progress.
This, uh, when we came to last year’s summit, we were at the very beginning of the journey with true Neuro, where we had had a beta group and we had connected with that beta group. And, and then we had launched the, the software and now a year later with clinics across the country using the software and, um, and now data being collected in a way that can help take the movement forward.
It’s, uh, it’s exciting to be here another year. And, you know, over the next year, our goal is to, first and foremost. Create accessibility for every state in America. You know, our goal is really that in every state you’ll be able to access care that is not only proven to reverse cognitive decline or connect with C clinicians who are in the process of learning how to do that and doing it successfully.
Also that the network itself and and practitioners using a similar methodology and collecting data together might be able to take the field forward because I also feel that we haven’t reached the endpoint of this as the standard of care. And it seems to me that like what has been proven is that this is possible when you detect the network insufficiency in the right way and then treat accordingly.
It’s my thinking that there’s, there’s still a long way to go in easing that process to make it as logistically simple and as clinically simple and as particip simple, you know, so that ultimately, ’cause I think it would have to be all of those things in order to become the standard of care. But I feel like we’ve taken a lot of ground in, in year one.
I agree with you. I think you know, the implementation of this can be a heavy lift both for patients and families and also for the practitioners and their teams, but the outcomes are just nothing short of miraculous. And when you get to Live Miracles day after day, that gives you a lot of motivation to keep going.
Exactly. Well, this is a warm invitation for everyone listening to join us at the summit coming up in April. We’ll have all the details in the show notes, but please join us. You can listen to all of the, the great lectures that we’ve been sort of previewing as well as last year where we had in incredible number of concepts.
I mean, you think. When you’re looking at understanding network sufficiency, you really have to deal with, with understanding how does metabolic inflammation play a role in cognitive decline and what could you do about it? The same thing for mitochondria and hormonal and cardiovascular and biotoxin and toxin.
And so in this summit you’ll, from leaders in the field about how they understand that process, what some of the tools that they use, and we’re really excited to be. Able to bring this out. I highly recommend being on also the, the session with Dr. Bredeson and Dr. Tues and Dr. Burke because that is really, you know, uh, an incredible opportunity to learn from the people on the cutting edge.
And we will be making it easier and easier for you to find practitioners that can do this and to, uh, eventually try and make a way that, um, this could become. A standard of care for cognitive decline and, uh, preventing and reversing it. So, Dr. Burke, thank you so much for your pioneering work. It’s been great to work together this year, and very excited for what’s to come.
And thank you for everyone, for listening. For those of you who have listened, who have paid attention, who have participated. And for all of those who are interested in finding out more, definitely get in touch with us. You can go to true neuro.com and you can look at find a practitioner. If you’re looking for a, a new practitioner, uh, we would love to meet you if you’re adopt doing precision and functional medicine already.
If you would like to become a node in our network, we would love to hear from you and, uh, we would love to support you in, uh, supporting patients like this. So. Thanks so much for tuning in for the summit. It’s gonna be a great session and we’ll see you next time. So that was the podcast. What an epic session.
And just a reminder that coming up in April, we will have version two of our Reversing Alzheimer’s Summit, and we’re gonna have updates on some of the new studies from Dr. Bresson and, uh, be charting a path forward for the reversal of Alzheimer’s and cognitive decline. Thank you so much for tuning in to the Evolution of Madison Podcast.
We’ll be back again next week and thanks so much for tuning in, and we’ll see you next time.
.
Subscribe
Download
Click here to download this podcast
music provided by intomusic.co
